Stockscreener 앱 받기
5.67
1.80%
0.10
전일 마감가:
$5.57
열려 있는:
$5.64
하루 거래량:
482.62K
Relative Volume:
0.47
시가총액:
$362.53M
수익:
-
순이익/손실:
$-119.87M
주가수익비율:
-3.1326
EPS:
-1.81
순현금흐름:
$-109.90M
1주 성능:
+11.18%
1개월 성능:
-1.90%
6개월 성능:
-39.74%
1년 성능:
-40.44%
1일 변동 폭
$5.44
$5.83
1주일 범위
$5.00
$5.90
52주 변동 폭
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
5.67 | 362.53M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
(ORIC) Long Term Investment Analysis - news.stocktradersdaily.com
ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oncology Biotech ORIC Issues Major Equity Package: 32,400 Options Plus RSUs for New Talent - Stock Titan
An analyst sees good growth prospects for ORIC Pharmaceuticals Inc (ORIC) - Sete News
Market Watch: ORIC Pharmaceuticals Inc (ORIC)’s Noteworthy Drop, Closing at 5.57 - DWinneX
Adage Capital Partners GP L.L.C. Has $4.04 Million Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Is ORIC Pharmaceuticals Inc (ORIC) worth investing in despite its overvalued state? - uspostnews.com
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Legal & General Group Plc - Defense World
ORIC Pharmaceuticals Inc’s Shares Reel: -51.58% Quarterly Revenue Decline Amid 401.98M Market Cap - investchronicle.com
ORIC Pharmaceuticals Inc (ORIC) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
79,900 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Acquired by Natixis - MarketBeat
ORIC-944 shows promise in prostate cancer treatment - Investing.com
ORIC Pharmaceuticals Highlights Promising Preclinical Data on OR - GuruFocus
ORIC Pharmaceuticals Presents Preclinical Data To Support The Potential Of Oric-944 As A Best-In-Class PRC2 Inhibitor For The Treatment Of Prostate Cancer - marketscreener.com
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by Silverarc Capital Management LLC - MarketBeat
Diadema Partners LP Invests $1.73 Million in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Average PT from Analysts - MarketBeat
A Look At The Behavior Of ORIC Pharmaceuticals Inc (ORIC) Stock - Stocksregister
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.86 - Defense World
ORIC Pharmaceuticals Inc (ORIC) produces promising results - uspostnews.com
Market Watch Highlights: ORIC Pharmaceuticals Inc (ORIC) Ends on an Downturn Note at 5.17 - DWinneX
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Position Increased by Geode Capital Management LLC - Defense World
ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech - Seeking Alpha
ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans (NASDAQ:ORIC) - Seeking Alpha
Alliancebernstein L.P. Trims Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
How the (ORIC) price action is used to our Advantage - news.stocktradersdaily.com
Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds? - MSN
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Vanguard Group Inc. - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Wellington Management Group LLP - Defense World
Corebridge Financial Inc. Has $247,000 Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by American Century Companies Inc. - Defense World
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - MSN
NEOS Investment Management LLC Buys New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Strengthens Team with Strategic Equity Grants to Key New Hires - Stock Titan
ORIC stock touches 52-week low at $5.24 amid market challenges - Investing.com
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - The AM Reporter
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Consensus Target Price from Analysts - MarketBeat
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan
Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
115,615 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
| Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
0.47%
2.63%
자본화:
|
볼륨(24시간):